Back to search
FDAFDA · Food and drugs·Recall number D-0572-2025

Xolair (omalizumab injection), 75 mg/0.5 ml, Rx only, Genentech, Inc., South San Francisco, CA 94080, NDC 50242-214-55

Published August 13, 2025 · Recall initiated: July 30, 2025

Summary

FDA records drug Class II recall D-0572-2025, published August 13, 2025 and initiated July 30, 2025. Recalling firm: Cardinal Health Inc.; Status: Ongoing; Reported quantity: 4 units; Lot: Lot: 3630004, Expires: 10/31/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Cardinal Health Inc.
Distributor
Nationwide Within the U.S.
Lot
Lot: 3630004, Expires: 10/31/2025.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Xolair (omalizumab injection), 75 mg/0.5 ml, Rx only, Genentech, Inc., South San Francisco, CA 94080, NDC 50242-214-55 recalled?

Yes. FDA published recall D-0572-2025 on August 13, 2025. Reported hazard: CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

What should I do if I have this product?

Voluntary: Firm initiated · Letter